CellCentric develops novel small molecule inhibitors to combat cancer

p300/CBP bromodomain inhibitors

Our science

Our work draws on a foundation in epigenetics and its application to novel drug discovery.

We are focused on developing first-in-class inhibitors of p300 and CBP, twin paralogue histone acetyltransferase (HAT) proteins that play a critical role in gene regulation within cancer cells.

CellCentric’s small molecule drug candidate binds to the conserved bromo-domain of p300/CBP, and significantly reduces the key drivers of castration resistant prostate cancer. These include the androgen receptor (AR), AR-splice variants and c-Myc.

Targeting p300/CBP is also relevant to the treatment of other cancers including haematological, lung and bladder.
More on our research

Our team

CellCentric’s team has deep experience of drug discovery and development, as well as business collaboration

The company is asset-centric, with a core team operating with a diverse range consultants and specialist contract research organisations

Press releases
See more

Twitter
(Follow us)

CCS1477 aimed at prostate cancers resistant to 2nd gen anti-hormonals (enza, abi, apa). pic.twitter.com/rZf5XugCfw

PCF Challenge Award underway investigating CCS1477 and p300/CBP bromodomain inhibition for prostate cancer. pic.twitter.com/4A0Z5pU0tQ